Careful consideration should be given when making assumptions about dose-response in NMA.
U
Standard NMA models were extended to account for dose response and class effects, building on the methods proposed by Del Giovane et al 2 . We adopt further notation so that x j,k t j,k and c j,k are used to index the dose, treatment and class respectively for intervention j in study k. One level models were fitted at each level, i.e:
We also fitted a 3-level exchangeable variance model where, as well as doses being exchangeable within treatment, effect sizes at the treatment level were also considered exchangeable within class, i.e:
Where  2 is a common variance parameter for effect sizes across the different treatments and  2 denotes a common variance parameter for effect sizes across the different classes.
We also extended the monotonic non-parametric dose-response model proposed by Del Giovane et al 2 . For this model (3-levMono) we assume that the increments in effectiveness between doses of the same treatment can be represented by a latent variable z which is strictly >0, i.e:
Effect sizes at the lowest dose are then assumed exchangeable within each treatment and these treatment level effects are assumed exchangeable within classes in a similar way to the 3-levT model. Effect sizes for each treatment and class were estimated by calculating an inverse variance weighted average using postestimation to avoid the confounding bias associated with taking the simple geometric mean.
Models were fitted using MCMC in OpenBUGS; flat normal priors were given to all location parameters and uniform or half-normal priors were given to all standard deviation parameters. All models were run for 300,000 iterations with a 100,000 burn-in and convergence was by visual inspection of plots. We compared all fitted models in terms of DIC, posterior residual deviance and heterogeneity.
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The objective of this study was to explore multi-level NMA models where interventions could be compared at the dose, treatment and class levels and the utility of these models in explaining heterogeneity, improving model fit and increasing precision of treatment effects
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Statistics pertaining to model fit can be found in table 1. Treatment effects for different doses of sumatriptan vs placebo with associated credible intervals for 1-levD and 3-levMono can be seen in figure 3 . This is intended to show that using a multi-level structure, i.e. allowing doses of the same intervention to borrow information from each other leads to more precise estimates of treatment effect. Estimated treatment effects from all the models vs placebo for sumatriptan can be seen in figure 4 . This is intended to show how models making different assumptions around doseresponse will estimate treatment effects at different doses.
3-levMono was the best model in terms of DIC and heterogeneity (Table 1) . This model also produced the most precise treatment effects (Figure 3 ). It can be seen from comparing the models that the improvement in model DIC was due to a reduction in effective parameters rather than a substantive improvement in fit as residual deviances are very similar.
3-levExch had higher heterogeneity and poorer fit than both the 1-levD and 3-levMono models and failed to capture the monotonic nature of the dose-response. This is due to the fact that imposing exchangeability causes all the effect sizes to be pulled towards the overall mean. In general we expect dose-response to be monotonic and therefore the exchangeability assumption is violated since we know a-priori which effect sizes are likely to be higher. This approach should therefore be used with caution and only if there is very strong reason to believe a-priori that the doseresponse is flat.
3-levMono appeared to underestimate the effect size for sumatriptan 200 mg; this is likely due to lack of data on the 200 mg dose and the fact that there is no information on intermediate doses (i.e. 100-200 mg)
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Conducting a Network Meta-Analysis (NMA) involves synthesising relative treatment effects from Randomised Controlled Trials (RCTs) comparing several different treatments 1 .
Grouping and splitting treatments (e.g by dose) is important both from a methodological and a decision making perspective 2 . An analysis conducted with interventions grouped either at the 'treatment' or 'class' levels will inevitably show more heterogeneity, but a network split too thinly will be less powered to detect meaningful differences between interventions and may not actually be connected.
The decision to group or split is often informed by the decision making perspective. Clinicians may favour an approach where interventions are grouped and compared at the class level allowing flexibility to recommend specific treatments to individual prescribing clinicians. Decision makers making recommendations on the basis of costeffectiveness may prefer a splitting approach since individual treatments and doses are associated with specific costs and outcomes.
While arguments can be made for grouping and splitting, each is associated with disadvantages. If doses are grouped a comparison at the dose level is not possible and therefore a fully informed decision cannot be made between competing doses of the same intervention. Information regarding heterogeneity that arises due to grouping of doses is also lost. Analyses conducted at the dose level make the assumption that all treatment dosages have distinct effects and therefore may lead to less precision in estimation of effect sizes since doses of the same treatment will not borrow information from each other. We used four previously conducted Cochrane reviews 3-6 in aspirin, diclofenac, ibuprofen and sumatriptan for acute pharmacological treatment of migraine as the data source.
Network meta-analysis models were developed to account for 'dose', 'treatment' and 'class' effects simultaneously and applied to the collected data; a schematic of the intervention hierarchy modelled is shown in Figure 1. 'Pain free at 2 hours' was chosen as the main outcome of interest. The network of RCT evidence is shown in figure 2 We fitted standard one level network meta-analysis models at the dose, treatment and class levels simultaneously and compared them to multi-level models accounting for doseresponse and/or class effects.
For multi-level models we built selected non-parametric models proposed by Del Giovane et al 2 and extended them to account for class effects. We start with the standard definition of a one level NMA as proposed by Cooper et al 7 .
-r jk , p jk and n jk denote the number of events, probability of event and number at risk respectively in arm k of trial j - jb is the log odds for treatment b in trial j - jbk and d bk are the study specific and pooled log odds ratios for treatment k relative to treatment b in trial j 
